Total trials
686
Active
66
Phase 3
213
Total enrollment
255,596
Pipeline matrix
Showing 40 of 102 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| B/F/TAF | — | 25 | |||||
| F/TAF | — | — | — | 12 | |||
| ATV | — | — | — | 13 | |||
| DRV | — | — | — | 9 | |||
| Cobicistat | — | — | — | 3 | |||
| E/C/F/TAF | — | — | — | 18 | |||
| 3rd ARV agent | — | — | — | — | 3 | ||
| Nucleos | — | — | — | — | — | 1 | |
| Lopinavir Boosted with ritonavir | — | — | — | — | — | 1 | |
| Sacituzumab Govitecan-hziy | — | — | — | 21 | |||
| Lenacapavir | — | — | 14 | ||||
| Zimberelimab | — | — | — | 11 | |||
| Paclitaxel | — | — | — | 11 | |||
| Carboplatin | — | — | — | 12 | |||
| Nab-paclitaxel | — | — | — | 8 | |||
| Pembrolizumab | — | — | — | — | 6 | ||
| Domvanalimab | — | — | — | — | 5 | ||
| Gemcitabine | — | — | — | 10 | |||
| Cisplatin | — | — | — | 7 | |||
| Oral Lenacapavir | — | — | — | 6 | |||
| Docetaxel | — | — | — | 8 | |||
| Teropavimab | — | — | — | 4 | |||
| Zinlirvimab | — | — | — | 4 | |||
| F/TDF | — | — | — | — | — | 4 | |
| Subcutaneous Lenacapavir | — | — | — | 4 | |||
| Bictegravir | — | — | — | — | 4 | ||
| Capecitabine | — | — | — | — | — | 4 | |
| GS-3242 | — | — | — | 3 | |||
| Pemetrexed | — | — | — | 3 | |||
| Sacituzumab Govitecan | — | — | — | — | 3 | ||
| Optimized Background Regimen | — | — | — | — | 2 | ||
| PTM F/TDF | — | — | — | — | — | 2 | |
| PTM Oral LEN | — | — | — | — | — | 2 | |
| ISL/LEN | — | — | — | — | — | 2 | |
| BIC/LEN FDC | — | — | — | — | — | 2 | |
| Cabotegravir | — | — | — | — | 2 | ||
| Tenofovir DF | — | — | — | 9 | |||
| TDF Placebo | — | — | — | — | 10 | ||
| Seladelpar | — | — | — | 5 | |||
| F/TAF Placebo | — | — | — | — | — | 5 |
62 more active programs hidden
Next readouts
- 2017-08-07
- 2019-01-31
- 2020-10-05
- 2021-08-06
- 2023-11-29
- 2023-12-19
- 2024-05-27
- 2024-07-02
- 2024-08-21
- 2025-01-15
Top conditions
- HIV Infections72
- Hepatitis C Virus Infection46
- HIV-1 Infection32
- Chronic Hepatitis B30
- Hepatitis C23
- HIV-1-infection23
- Cystic Fibrosis22
- HIV19
Frequently asked questions about Gilead Sciences
- How many clinical trials does Gilead Sciences have on ClinicalTrials.gov?
- Gilead Sciences is listed as the lead sponsor on 686 clinical trials in ClinicalTrials.gov, 66 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Gilead Sciences's trials are in Phase 3?
- 213 of Gilead Sciences's trials are in Phase 3, spread across 102 active drug programs.
- What therapeutic areas does Gilead Sciences focus on?
- Gilead Sciences's most-studied conditions on ClinicalTrials.gov are HIV Infections, Hepatitis C Virus Infection, HIV-1 Infection, Chronic Hepatitis B, Hepatitis C.
- When are Gilead Sciences's next clinical trial readouts?
- Gilead Sciences has 10 upcoming primary-completion readouts tracked here; the soonest is “Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection”, expected around 2017-08-07.